New E. coli system produces over 30 mg of pure p53pAnt peptide per gram of cell mass, but fails to cleave PNC27
Background
Peptide pharmaceuticals with intracellular targets represent a promising but challenging area of research. These peptides can modulate processes within the cell or interfere with signaling pathways, opening new therapeutic possibilities. However, many bioactive sequences require fusion to a cell-penetrating peptide (CPP) to gain entry into the cell. This fusion can result in a longer peptide that is difficult and costly to produce using traditional chemical synthesis methods. Anticancer peptides derived from proteins like p53 are a key example. Developing a flexible, high-yield recombinant expression and purification system is crucial to overcoming these manufacturing barriers and enabling the discovery and development of these potentially powerful new drugs.
Study Design
Researchers designed and implemented a high-throughput recombinant expression and purification system in Escherichia coli. The system produces target peptides fused to a hexahistidine-tagged ketosteroid isomerase, rendering them insoluble for easier separation. A highly efficient thrombin cleavage reaction procedure was designed to release the final peptide. The system's efficacy was tested by expressing two anticancer peptides, p53pAnt (from the C-terminal region of p53) and PNC27 (from the N-terminal region of p53), both fused to the cell-penetrating peptide Penetratin.
Results
High yields of the purified, fused recombinant peptides were obtained for both p53pAnt and PNC27. The initial expression and purification steps were successful in both cases. However, the subsequent thrombin cleavage reaction, designed to separate the target peptide from its fusion partner, was only successful for releasing the p53pAnt peptide. The cleavage step failed for the PNC27 fusion peptide. The optimized procedure for p53pAnt was highly efficient, allowing for significant production scale.
The system, along with the developed procedure, achieved a high production yield of over 30 mg of highly pure p53pAnt peptide per gram of dry cell mass.
The authors propose that this system could be adapted for producing other peptides at similarly high yields, provided the cleavage step is successful.
Key Findings
- A new E. coli recombinant expression system was developed for producing cell-penetrating peptides.
- The system successfully produced high yields of fused p53pAnt and PNC27 peptides.
- Thrombin cleavage to release the final peptide was successful for p53pAnt but failed for PNC27.
- The optimized process yielded over 30 mg of highly pure p53pAnt per gram of dry cell mass.
Why It Matters
This study provides a proof-of-concept for a scalable and efficient method of producing complex, cell-penetrating peptides, which are often difficult to synthesize. For researchers working with peptides like p53pAnt, this system offers a viable alternative to expensive chemical synthesis, potentially accelerating preclinical research and biological assays. However, the failure to cleave PNC27 highlights a critical limitation: the system is not universally applicable and its success is peptide-sequence dependent. Researchers must validate the thrombin cleavage step for each new peptide sequence. This work is a step towards more accessible research-grade peptide production but is far from a universally applicable clinical manufacturing protocol.
peptide synthesis
recombinant expression
pnc-27
p53
in vitro
biotechnology
